Announcements Trials
Browse Landscape

Phase

Phase 1 36Phase 2 26Phase 1/2 24Phase 3 7Phase 4 5Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Unknown 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1Neoplasms 1Cytokine Release Syndrome 1Cancer Therapy-related Cardiovascular Toxicity 1Arthritis, Rheumatoid 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 4 × tocilizumab × Clear all
NCT07609940 2026-05-27

POPLIN

Regeneron Pharmaceuticals

Phase 4 Not yet recruiting
30 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

University Health Network, Toronto

Phase 4 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT05855122 2023-06-02

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

The First Affiliated Hospital of Soochow University

Phase 4 Unknown
48 enrolled
Plasma cell

Multiple Myeloma

NCT05730777 2023-02-16

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

Peking University Third Hospital

Phase 4 Unknown
200 enrolled

Cancer Therapy-related Cardiovascular Toxicity

NCT01283971 2014-02-10

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Hoffmann-La Roche

Phase 4 Terminated
96 enrolled 27 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡